Related Experiment Video
Updated: Aug 3, 2026
11:27
A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
Published on: August 9, 2022
Formulation of fast release glibenclamide liquid and semi-solid matrix filled capsules
Saly Galal1, Magda El-Massik, Ossama Abdallah
1Department of Pharmaceutics, Faculty of Pharmacy, University of Alexandria, Egypt. magdaelmassik@yahoo.com
Acta Pharmaceutica (Zagreb, Croatia)
|February 11, 2004
Summary
Liquid and semi-solid matrix (SSM) capsule technology enhances glibenclamide (GBD) dissolution. GBD solubility was optimized using tetraglycol, achieving comparable release profiles in various formulations.
Area of Science:
- Pharmaceutical Technology
- Drug Delivery Systems
- Physical Pharmacy
Background:
- Glibenclamide (GBD) exhibits poor aqueous solubility, limiting its oral bioavailability.
- Enhancing dissolution rate is crucial for improving the therapeutic efficacy of poorly soluble drugs like GBD.
- Liquid and semi-solid matrix (SSM) formulations offer potential for solubility enhancement.
Purpose of the Study:
- To investigate the efficacy of liquid and SSM capsule technology in improving the dissolution rate of glibenclamide (GBD).
- To identify optimal vehicles for GBD solubilization and formulation.
- To evaluate the dissolution profiles of GBD from different capsule formulations.
Main Methods:
- Semiquantitative estimation of GBD solubility in various vehicles.
- Formulation of GBD as solutions in tetraglycol or tetraglycol/PEG 6000 blend.
- Formulation of GBD as suspensions in SSM using Gelucire 44/14.
- Dissolution rate studies of prepared capsule formulations.
Main Results:
- Tetraglycol was identified as the most effective solubilizer for glibenclamide.
- GBD formulations included solutions and SSM suspensions with varying drug concentrations.
- Comparable GBD release profiles were observed from capsule formulations up to 3.5% (m/m) drug concentration.
Conclusions:
- Liquid and SSM capsule technologies are effective in enhancing glibenclamide dissolution.
- Tetraglycol-based formulations and SSM suspensions demonstrate potential for improved GBD delivery.
- The developed formulations show promise for achieving consistent drug release characteristics.
Related Concept Videos
01:28Factors Influencing Drug Absorption: Pharmaceutical Parameters
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
01:22Modified-Release Drug Delivery Systems: Rate-Programmed I
Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...